Breaking Finance News

A statement released earlier today by SunTrust about Clovis Oncology (NASDAQ:CLVS) bumps the target price to $50.00

In a statement issued on 9/23/2016 SunTrust upped the stock price target of Clovis Oncology (NASDAQ:CLVS) from $38.00 to $50.00 indicating a possible upside of 0.30%.

Just yesterday Clovis Oncology (NASDAQ:CLVS) traded 2.06% higher at $38.36. CLVS’s 50-day average is $23.50 and its two hundred day average is $17.45. The last close is up 124.39% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time. 930,748 shares of Clovis Oncology exchanged hands, down from an avg. volume of 2,551,230

Performance Chart

Clovis Oncology (NASDAQ:CLVS)

With a total market value of $0, Clovis Oncology has with a one year low of $11.57 and a 52 week high of $109.18 .

In addition to SunTrust reporting its target price, a total of 8 brokerages have issued a ratings update on the company. The average stock price target is $17.50 with 2 firms rating the stock a strong buy, zero equity analysts rating the stock a buy, 6 brokerages rating the company a hold, 0 analysts rating the company a underperform, and lastly zero brokerages rating the company a sell.

Brief Synopsis About Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.